<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190308042966N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-10-30</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Effect of topical nanoliposomes gel containing curcumin (Sinanumin) in improving stomatitis aphthous in patients with Behcet's disease compared to Triamcinolone Acetonide</public_title>
      <acronym></acronym>
      <scientific_title>Effect of topical nanoliposomes gel containing curcumin (Sinanumin) in improving stomatitis aphthous in patients with Behcet's disease compared to Triamcinolone Acetonide</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/42462</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The method used to generate random allocation sequences using a random number table using randomiz.com so that envelopes are prepared and printed by a member of the Random Numbers Research Team with the help of Randomaize.com. Will take. The envelope door will be closed and its contents not visible from the outside. Then, the purpose of the study is first explained to the person who meets the requirements, and if the person wishes to sign the informed consent form, remove the envelope and then open it and enter the intervention or control group based on the contents of the individual envelope, Blinding description: The patient is unaware of the treatment and the blinding of the analyzer and the patient (double blind) is performed.</study_design>
      <phase>3</phase>
      <hc_freetext>Behcet's disease - Recurrent Oral aphthous.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the intervention group, Sina nanomedicine gel is used.Topical nano-liposomes containing curcumin (cyanomine) were made at the Nanotechnology Research Center of Mashhad University of Medical Sciences by Dr. Mahmoud Reza Jafari. The drug is made of curcumin yellow active ingredient. intervention grou benefit from standard treatment of Behcet's oral aphthous treatment, including colchicine. On day 0, 3, 7 patients were examined for the number and size of wounds and daily pain score. On day 0 the patient was examined for the number and size of the wounds and the pain score. The longest wound diameter measured using a sterile Vernier caliper is recorded as the wound size, and pain scores are reported using the Visual Analogue Scale (VAS) of zero to 10. Patients are also examined on days 3 and 7 to check for a decrease in the number and size of wounds. Pain scores are also recorded daily. Intervention 2: Control group: In the control group is used triamcinolone acetone gel. Control group benefit from standard treatment of Behcet's oral aphthous treatment, including colchicine. On day 0, 3, 7 patients were examined for the number and size of wounds and daily pain score. On day 0 the patient was examined for the number and size of the wounds and the pain score. The longest wound diameter measured using a sterile Vernier caliper is recorded as the wound size, and pain scores are reported using the Visual Analogue Scale (VAS) of zero to 10. Patients are also examined on days 3 and 7 to check for a decrease in the number and size of wounds. Pain scores are also recorded daily.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyed farzam Mircheraghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>International Students Admission Committee, International Office, Chancellory Building, Mashhad University of Medical Sciences, Mashhad, P.O. Box: 91735-951, I. R. IRAN.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177817022</zip>
        <telephone>+98 51 3870 0349</telephone>
        <email>mircheraghif961@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed farzam Mircheraghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>International Students Admission Committee, International Office, Chancellory Building, Mashhad University of Medical Sciences, Mashhad, P.O. Box: 91735-951, I. R. IRAN.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177817022</zip>
        <telephone>+98 51 3870 0349</telephone>
        <email>mircheraghif961@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients between the age of 14 and 50 years with sufficient literacy and knowledge to provide explanations</inclusion_criteria>
      <agemin>14 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Traumatic oral ulcer
 Patients with dentures
 Aphthous in inaccessible areas
Patients who suffer from any systemic disease causing immunodeficiency (diabetes and ESRD ...)
Patients with any major disease in the past
Use of any systemic treatment, including use of any type of immunosuppressive drug
Patients who are allergic to sinanomine at baseline or during the study
Pregnant or lactating women
People who cannot continue their studies for personal or social reasons</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K12.0  M35</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Behcet's disease</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the intervention group, Sina nanomedicine gel is used.Topical nano-liposomes containing curcumin (cyanomine) were made at the Nanotechnology Research Center of Mashhad University of Medical Sciences by Dr. Mahmoud Reza Jafari. The drug is made of curcumin yellow active ingredient. intervention grou benefit from standard treatment of Behcet's oral aphthous treatment, including colchicine. On day 0, 3, 7 patients were examined for the number and size of wounds and daily pain score. On day 0 the patient was examined for the number and size of the wounds and the pain score. The longest wound diameter measured using a sterile Vernier caliper is recorded as the wound size, and pain scores are reported using the Visual Analogue Scale (VAS) of zero to 10. Patients are also examined on days 3 and 7 to check for a decrease in the number and size of wounds. Pain scores are also recorded daily.</i_keyword>
      <i_keyword>Control group: In the control group is used triamcinolone acetone gel. Control group benefit from standard treatment of Behcet's oral aphthous treatment, including colchicine. On day 0, 3, 7 patients were examined for the number and size of wounds and daily pain score. On day 0 the patient was examined for the number and size of the wounds and the pain score. The longest wound diameter measured using a sterile Vernier caliper is recorded as the wound size, and pain scores are reported using the Visual Analogue Scale (VAS) of zero to 10. Patients are also examined on days 3 and 7 to check for a decrease in the number and size of wounds. Pain scores are also recorded daily.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Mean pain score between two groups after intervention. Timepoint: Day 0, 3 and 7. Method of measurement: Caliper Vernier Ruler.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-05-28</approval_date>
        <contact_name>Research Ethics Committee of School of Medicine- Mashhad University of Medical Sciences</contact_name>
        <contact_address>University Street, Central Building of Mashhad University of Medical Sciences (Qurishi) Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
